Evidence Snapshot

Epithelial discoidin domain-containing receptor 1

CHEMBL5319 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:39Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:05 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5319

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Epithelial discoidin domain-containing receptor 1 as ChEMBL target CHEMBL5319, mapped to UniProt Q08345. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Epithelial discoidin domain-containing receptor 1

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL5319

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q08345

Epithelial discoidin domain-containing receptor 1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Epithelial discoidin domain-containing receptor 1 matters

As of 2026-09-13

Epithelial discoidin domain-containing receptor 1 is reviewed as Epithelial discoidin domain-containing receptor 1 (UniProt Q08345); the current evidence base includes 28 approved drugs, 2218 compounds, and 402 assays, with lead potency reaching pChEMBL 9.7.

Protein context

Epithelial discoidin domain-containing receptor 1

Epithelial discoidin domain-containing receptor 1 Sequence length is 913 aa.

Review this target as Epithelial discoidin domain-containing receptor 1, mapped to UniProt Q08345. Sequence length is 913 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q08345 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 28 approved drugs, 2218 compounds, and 402 assays for this target. The dominant activity type is IC50. CHEMBL1230609 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL1230609 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine

28 approved pChEMBL 9.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Epithelial discoidin domain-containing receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q08345, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2218

Total Compounds

402

Total Assays

Approved Drugs

IC50: 1708.0, KI: 1.0, EC50: 4.0, KD: 397.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL1230609	9.7	Kd	Clinical
No preferred name CHEMBL3907057	9.4	Kd	—
No preferred name CHEMBL5416410	9.3	IC50	Approved
No preferred name CHEMBL2336015	9.2	Kd	—
No preferred name CHEMBL5416410	9.2	Kd	Approved

Approved Drugs

Structure	Compound	First Approval
	TOVORAFENIB CHEMBL3348923	2024
	QUIZARTINIB CHEMBL576982	2023
	TIVOZANIB CHEMBL1289494	2017
	LENVATINIB CHEMBL1289601	2015
	NINTEDANIB CHEMBL502835	2014
	REGORAFENIB CHEMBL1946170	2012
	AXITINIB CHEMBL1289926	2012
	PONATINIB CHEMBL1171837	2012
	CABOZANTINIB CHEMBL2105717	2012
	BOSUTINIB CHEMBL288441	2012
	CRIZOTINIB CHEMBL601719	2011
	VANDETANIB CHEMBL24828	2011
	PAZOPANIB CHEMBL477772	2009
	NILOTINIB CHEMBL255863	2007
	DASATINIB ANHYDROUS CHEMBL1421	2006
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005
	ERLOTINIB CHEMBL553	2004
	IMATINIB CHEMBL941	2001

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:39Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:05 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL5319